Not Yet Recruiting PHASE3 INTERVENTIONAL 3-arm NCT07230119

A Study of Zovaglutide in Subjects With Overweight or Obesity (HORIZON-1)

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study to Evaluate the Efficacy and Safety of Zovaglutide in Adults With Overweight or Obesity.

Sponsor: Beijing QL Biopharmaceutical Co.,Ltd

Conditions Overweight , Obesity

Interventions Placebo Zovaglutide dose 1 Zovaglutide dose 2

Updated 2 times since 2025 Last updated: Dec 17, 2025 Started: Mar 8, 2026 Primary completion: May 29, 2027 Completion: Jun 26, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT07230119, this PHASE3 trial focuses on Overweight , Obesity and remains actively recruiting participants. Sponsored by Beijing QL Biopharmaceutical Co.,Ltd, it has been updated 2 times since 2026, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

2 versions recorded

Jan 2026 — Present [monthly]

Not Yet Recruiting PHASE3
Dec 2025 — Jan 2026 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Beijing QL Biopharmaceutical Co.,Ltd

Data source: Beijing QL Biopharmaceutical Co.,Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Beijing, China , Guangzhou, China , Handan, China , Harbin, China , Huizhou, China , Jinan, China , Langfang, China , Lanzhou, China , Lianyungang, China , Luoyang, China and 12 more locations